Tuberculosis

Featured

Think scale! Engaging Private Pharmacies to Improve Public Health 

A version of this story first appeared on IDSA’s Science Speaks platform By Emily Delmotte Lisinopril 20 mg by mouth at 8am? Check. After verifying the Read More

Eliminate the TB Scourge – The New York Times

Tuberculosis is a problem worldwide. But little is being done to modernize our approach to this debilitating and deadly disease. Source: Eliminate the TB Scourge Read More

Device focuses on speedier tuberculosis diagnosis

Automated gadget magnifies and photographs samples and uses software to identify bacteria.

Latest

CROI 2017: Innovation, research tackle TB challenges

Categories: CROI 2017An “ultra”-sensitive test, and a proactive use of prednisone show promise, require monitoring SEATTLE – In the halting progress against tuberculosis in people living with HIV, advances in both diagnosis and effective treatment have come with gaps and caveats, highlighted, and then answered with research presented last week in sessions and press conferences dedicated to […](Read more…)


Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant…

Tuberculosis (TB) and multidrug-resistance tuberculosis (MDR-TB) pose serious challenges to global health, particularly in China, which has the second highest case burden in the world.


Delays and loss to follow-up before treatment of drug-resistant tuberculosis following…

by Helen Cox, Lindy Dickson-Hall, Norbert Ndjeka, Anja van’t Hoog, Alison Grant, Frank Cobelens, Wendy Stevens, Mark Nicol Background South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734 patients diagnosed in 2014. The number of diagnosed patients has increased substantially with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all patients with presumptive TB. Routine aggregate data suggest a large treatment gap (pre-treatment loss to follow-up) between the numbers of patients with laboratory-confirmed RR-TB and those reported to have started second-line treatment. We aimed to assess the impact of Xpert MTB/RIF implementation on the delay to treatment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa. Methods and findings A nationwide retrospective cohort study was conducted to assess second-line treatment initiation and treatment delay among laboratory-diagnosed RR-TB patients


Chasing a Cure for Melva in Peru

Photo by Silvia Chiang / Partners In HealthMelva Fernandez visits the Pacific Ocean for the first time with her father, Carlos. The 7-year-old was diagnosed with a rare immune disorder and is receiving care through PIH in Peru. By all appearances, Melva Fernandez is a typical 7-year-old girl. She adores the Disney movie Frozen, loves dolls and video games, and is—occasionally—a bit naughty.


Names Of 3 Finalists For Global Fund Executive Director Released

New York Times: A Contentious List of Finalists for Global Aid Fund Group’s Director “…The nominating committee of the [Global Fund to Fight AIDS, Tuberculosis and Malaria’s] board on Monday produced a report naming the three finalists and its rationale for picking them. … A senior United States government official said administration global health officials…More


2015 Influx Of Ebola Money Masks Declines In R&D Funding For Other Infectious, Neglected…

Nature: Ebola funding surge hides falling investment in other neglected diseases “Global funding for research on neglected diseases — which include tuberculosis, HIV/AIDS, and malaria — is at its lowest level since 2007, according to the annual G-FINDER investment report by Policy Cures Research, a health policy analysis firm in Sydney, Australia. But that total…More


CROI 2017: Continued Nix-TB regimen results take the kitchen sink out of XDR-TB treatment

Categories: CROI 2017Continued success of three-drug, six-month regimen introduces potential first gold standard of XDR-TB care SEATTLE – With a mortality rate of about 75 percent, tuberculosis that is extensively resistant to first and second-line treatments — XDR-TB — has left physicians with little choice aside from what Dr. Francesca Conradie calls the “kitchen sink” approach. That […](Read more…)


CROI 2017: More evidence that TB preventive therapy saves lives of people with HIV highlights…

Categories: CROI 2017SEATTLE – At CROI 2015 the results of the TEMPRANO trial showed that early initiation of antiretroviral therapy and six months of isoniazid preventive therapy significantly reduced illness including tuberculosis in patients with HIV.  On Wednesday, Anani Badje from the TEMPRANO group provided long-term follow-up results from this same study that confirmed the value of […](Read more…)


‘Science Speaks’ Reports On Findings Presented At 2017 Conference On Retroviruses And…

Center for Global Health Policy’s “Science Speaks”: CROI 2017: Science Speaks brings news from Seattle Antigone Barton, senior editor and writer of “Science Speaks,” writes, “The 2017 Conference on Retroviruses and Opportunistic Infections this week finds a growing research agenda informing and informed by science and strategy surrounding HIV as well as tuberculosis, hepatitis, and…More


Modelling approaches for tuberculosis: are they realistic? – Authors’ reply

In his Correspondence on our paper,1 Sachin Atre describes factors that could reduce the impact of intensified tuberculosis control, and questions the usefulness of mathematical modelling that ignores these challenges. On these points we wholeheartedly agree. As part of this modelling collaboration, we took steps to ensure that modelled strategies reflected real-world constraints—to the extent possible, assumptions about uptake, retention, quality, and other factors influencing policy outcomes were based on empirical programme experience, and stakeholders from national tuberculosis control programmes were involved throughout to define realistic policy scenarios and review modelled results.


Modelling approaches for tuberculosis: are they realistic?

The Article by Nicolas Menzies and colleagues (November, 2016),1 based on a modelling approach, concludes that most tuberculosis control interventions in South Africa, China, and India are highly cost-effective. In this regard, I have a different viewpoint.


Kaiser Family Foundation Releases Updated Fact Sheet On U.S. Government, Global TB Efforts

Kaiser Family Foundation: The U.S. Government and Global Tuberculosis Efforts This fact sheet explains the U.S. government’s role in addressing global tuberculosis (TB), including the history of U.S. involvement and funding trends (2/14).


Think scale! Engaging Private Pharmacies to Improve Public Health 

A version of this story first appeared on IDSA’s Science Speaks platform By Emily Delmotte Lisinopril 20 mg by mouth at 8am? Check. After verifying the Read More


Prevalence and clinical relevance of helminth co-infections among tuberculosis patients in…

by Francis Mhimbira, Jerry Hella, Khadija Said, Lujeko Kamwela, Mohamed Sasamalo, Thomas Maroa, Magreth Chiryamkubi, Grace Mhalu, Christian Schindler, Klaus Reither, Stefanie Knopp, Jürg Utzinger, Sébastien Gagneux, Lukas Fenner Background Helminth infections can negatively affect the immunologic host control, which may increase the risk of progression from latent Mycobacterium tuberculosis infection to tuberculosis (TB) disease and alter the clinical presentation of TB. We assessed the prevalence and determined the clinical relevance of helminth co-infection among TB patients and household contact controls in urban Tanzania. Methodology Between November 2013 and October 2015, we enrolled adult (≥18 years) sputum smear-positive TB patients and household contact controls without TB during an ongoing TB cohort study in Dar es Salaam, Tanzania


Older Posts »